International Circulation: It has been 13 years after the first TAVR， which is become the “Global” affairin the “Modern” era. Could you introduce how TAVR development gradually in Korea?

　　《国际循环》：经导管主动脉瓣置换术从第一例至今已有13年，现在已成为全球性事务。韩国的发展经历了哪些里程碑事件？

　　Dr. Park ： Actually in Korea we started TAVR procedures in 2013， actually up to this point， overall the number of TAVR to be 450 something. Actually it is balanced between the SAPIEN XT and Corevalve. I think this type of procedure increases the revolution of interventional cardiology and in the future we need a little more concern over TAVR and we have some positive results about that. Actually we are moving to the more intermediate， moderate risk of patients， and the TAVR type of procedure is growing. In Korea， as you may know， there are some essential need for the heart team to cooperate with the cardiac surgeon and the cost of the device is too so we have a lot of problems， however we are very slowly growing the TAVR procedure in Korea.

　　Park教授：韩国于2013年开始开展经导管主动脉瓣置换术（TAVR），截止到目前为止共计完成了450例，应用SAPIEN XT瓣膜与Corevalve瓣膜的数量基本相当。我认为TAVR促进了介入心脏病学领域的变革。我们现在已经获得了一些有关TAVR的积极结果。未来，我们需要更多地关注TAVR。实际上，目前我们已经逐渐开始对越来越多的中危患者行TAVR治疗。目前韩国存在需要构建心脏团队实现和促进心血管介入医生与心脏外科医生合作以及设备成本等方面的问题。但是，总体来说，韩国的TAVR还是在处于缓慢发展中。

　　International Circulation: What do you think is the global problem for the development and promotion of TAVR， and which are the unique to Asia countries?

　　《国际循环》：您认为有哪些是全球普遍存在的问题，哪些是亚洲国家所特有的？

　　Dr. Park :  Right， so I just mentioned about the main issues. I think there are 2 issues， mainly the devices are still too expensive. In China anyways， you have your own domestic TAVR devices but however globally， still there are insurance coverage problems. That is the first problem. The second one is that it is a very new concept of approach for the procedure. We need a heart team， essentially in cooperation with the cardiac surgeon and internalists. I think it is a very unique and first experience of terms of them working together， however a lot of the experience we have getting more of a smooth landing in terms of collaboration， I hope in the future the economic issues and price issues will improve. That is what I think the current issue is with TAVR.

　　Park教授：我刚才已经提到了TAVR发展所面临的主要问题。我认为，TAVR的发展面临两大问题，其中最主要的就是相关设备过于昂贵。中国虽然好在有自己研发的TAVR设备，但却仍存在医保无法覆盖的问题。这是第一个问题。第二个问题是，实施TAVR需要一种全新的方法和理念，需要构建心脏团队实现心脏外科医生与介入医生的合作。目前，就合作而言，我们已经积累了很多经验。我希望将来TAVR发展所面临的经济问题及价格问题能够得以改善。上述就是我对TAVR的个人见解。